Targeted therapy in metastatic renal cell carcinoma: efficacy, adverse-event management and key considerations

摘要

Renal cell carcinoma (RCC) accounts for approximately 2% of all cancers worldwide, with the highest rates observed in North America, Australia and Europe. In Europe, approximately 40,000 patients are diagnosed with RCC each year, leading to an estimated 20,000 deaths.